Working… Menu

AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00372944
Recruitment Status : Completed
First Posted : September 7, 2006
Last Update Posted : August 13, 2014
Information provided by (Responsible Party):

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : April 2008
Actual Study Completion Date : October 2008
Certification/Extension First Submitted : July 22, 2013